中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 6
Jun.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(6): 1246-1252

Long-term prognosis of recompensation in patients with decompensated liver cirrhosis

DOI: 10.12449/JCH260602

  • Department of Hepatology，Guangzhou Eighth People’s Hospital，Guangzhou Medical University，Guangzhou 510440，China

Research funding:

Medical Science and Technology Research Fund of Guangdong Province (A2024653);

Guangzhou Municipal-University/Institutes-Enterprises Joint Funding Project (2025A03J3731);

Guangzhou Municipal-University/Institutes-Enterprises Joint Funding Project (2024A03J0860);

Major Clinical Research Project of the Scientific Research Capacity Enhancement Program of Guangzhou Medical University (GMUCR2024-02027)

More Information
  • Corresponding author: WANG Yaping， xiruo0833@sina.com （ORCID： 0000-0002-0609-9115）
  • Received Date: 2026-03-15
  • Accepted Date: 2026-04-09
  • Published Date: 2026-06-25
    Abstract
  • Liver cirrhosis recompensation refers to the process in which patients with decompensated cirrhosis achieve the disappearance of decompensated complications and restoration of liver function and clinical phenotype to a compensated state after etiological treatment or symptomatic treatment. In recent years， with effective control of the etiology of cirrhosis and treatment or prevention of decompensated complications， the clinical significance of recompensation has gained increasing attention. This article elaborates on recompensation from the aspects of definition， diagnostic criteria， influencing factors， mechanisms affecting long-term prognosis， and clinical management strategies， and with reference to the latest research evidence， this article also discusses the core value of recompensation in improving quality of life and reducing the risk of end-stage events， in order to provide a basis for optimizing the comprehensive management of liver cirrhosis.

     

    • FullText(HTML)
  • loading
    • References(48)
  • [1]
    Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
    [2]
    JU YC, JUN DW, CHOI J, et al. Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis[J]. World J Gastroenterol, 2018, 24( 40): 4606- 4614. DOI: 10.3748/wjg.v24.i40.4606.
    [3]
    D’AMICO G, GARCIA-TSAO G, PAGLIARO L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies[J]. J Hepatol, 2006, 44( 1): 217- 231. DOI: 10.1016/j.jhep.2005.10.013.
    [4]
    LI MY, ZONG Z, XIONG XM, et al. Ascites re-compensation in HBV-related first decompensated cirrhosis after anti-viral therapy[J]. Front Cell Infect Microbiol, 2023, 12: 1053608. DOI: 10.3389/fcimb.2022.1053608.
    [5]
    HUI VW, WONG GL, WONG VW, et al. Baveno VII criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis[J]. JHEP Rep, 2023, 5( 9): 100814. DOI: 10.1016/j.jhepr.2023.100814.
    [6]
    HOFER BS, SEMMLER G, SIMBRUNNER B, et al. Course of portal hypertension and applicability of noninvasive tests after recompensation in alcohol-related cirrhosis[J]. Clin Gastroenterol Hepatol, 2026, 24( 4): 1175- 1178. DOI: 10.1016/j.cgh.2025.07.021.
    [7]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites and complications in cirrhosis[J]. J Clin Hepatol, 2017, 33( 10): 1847- 1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003.

    中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33( 10): 1847- 1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003.
    [8]
    WANG Q, ZHAO H, DENG Y, et al. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis[J]. J Hepatol, 2022, 77( 6): 1564- 1572. DOI: 10.1016/j.jhep.2022.07.037.
    [9]
    ARAVINTHAN AD, BARBAS AS, DOYLE AC, et al. Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: A case-control study[J]. Transpl Int, 2017, 30( 11): 1140- 1149. DOI: 10.1111/tri.13008.
    [10]
    HE ZY, WANG BQ, YOU H. Reversal of cirrhotic decompensation: re-compensation[J]. Chin J Hepatol, 2019, 27( 12): 915- 918. DOI: 10.3760/cma.j.issn.1007-3418.2019.12.002.

    何志颖, 王冰琼, 尤红. 肝硬化失代偿的逆转: 再代偿[J]. 中华肝脏病杂志, 2019, 27( 12): 915- 918. DOI: 10.3760/cma.j.issn.1007-3418.2019.12.002.
    [11]
    REIBERGER T, HOFER BS. The Baveno VII concept of cirrhosis recompensation[J]. Dig Liver Dis, 2023, 55( 4): 431- 441. DOI: 10.1016/j.dld.2022.12.014.
    [12]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B[J]. Infect Dis Inf, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 传染病信息, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.
    [13]
    KIM TH, UM SH, LEE YS, et al. Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy[J]. Aliment Pharmacol Ther, 2022, 55( 1): 83- 96. DOI: 10.1111/apt.16658.
    [14]
    GOH XE, GOH MX, CHEN VL, et al. Prevalence and clinical outcomes of recompensation in decompensated cirrhosis: A systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2026, 24( 4): 911- 922. DOI: 10.1016/j.cgh.2025.08.010.
    [15]
    HE ZY, WANG BQ, WU XN, et al. Recompensation in treatment-naïve HBV-related decompensated cirrhosis: A 5-year multi-center observational study comparing patients with ascites and bleeding[J]. Hepatol Int, 2023, 17( 6): 1368- 1377. DOI: 10.1007/s12072-023-10579-w.
    [16]
    XU DQ, MU H, ZHANG YY, et al. Influencing factors for recompensation in patients with decompensated hepatitis C cirrhosis[J]. J Clin Hepatol, 2025, 41( 2): 269- 276. DOI: 10.12449/JCH250212.

    许丹青, 木唤, 张映媛, 等. 丙型肝炎肝硬化失代偿患者再代偿的影响因素分析[J]. 临床肝胆病杂志, 2025, 41( 2): 269- 276. DOI: 10.12449/JCH250212.
    [17]
    SEMMLER G, LENS S, HIDALGO Á, et al. Incidence and clinical significance of recompensation after HCV cure[J]. Clin Gastroenterol Hepatol, 2025, 23( 13): 2488- 2498.e8. DOI: 10.1016/j.cgh.2025.04.026.
    [18]
    PREMKUMAR M, DHIMAN RK, DUSEJA A, et al. Recompensation of chronic hepatitis C–related decompensated cirrhosis following direct-acting antiviral therapy: Prospective cohort study from a hepatitis C virus elimination program[J]. Gastroenterology, 2024, 167( 7): 1429- 1445. DOI: 10.1053/j.gastro.2024.08.018.
    [19]
    HOFER BS, TONON M, BUTTLER L, et al. Incidence and implications of abstinence-induced recompensation in alcohol-related cirrhosis[J]. J Hepatol, 2026. DOI: 10.1016/j.jhep.2026.01.007.[ Epub ahead of print]
    [20]
    HOFER BS, SIMBRUNNER B, HARTL L, et al. Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis[J]. Liver Int, 2023, 43( 10): 2220- 2231. DOI: 10.1111/liv.15676.
    [21]
    HOFER BS, BURGHART L, HALILBASIC E, et al. Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis[J]. Aliment Pharmacol Ther, 2024, 59( 8): 962- 972. DOI: 10.1111/apt.17908.
    [22]
    SHEN L, LV TT, LI SX, et al. Factors associated with recompensation and criteria for etiological suppression in patients with primary biliary cholangitis[J]. J Gastroenterol, 2026, 61( 2): 195- 206. DOI: 10.1007/s00535-025-02342-9.
    [23]
    RONG XX, YANG GD, XU YY, et al. Efficacy and safety of tenofovir amibufenamide and tenofovir alafenamide for first-time HBV-related decompensated cirrhosis[J]. J Viral Hepat, 2025, 32( 4): e14029. DOI: 10.1111/jvh.14029.
    [24]
    SHI H, LI XY, ZHU JY, et al. Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: A comparative analysis[J]. Chin J Hepatol, 2017, 25( 10): 721- 725. DOI: 10.3760/cma.j.issn.1007-3418.2017.10.001.

    时红, 李向永, 朱建芸, 等. 恩替卡韦和替诺福韦酯治疗高病毒载量HBeAg阳性慢性乙型肝炎的对比分析[J]. 中华肝脏病杂志, 2017, 25( 10): 721- 725. DOI: 10.3760/cma.j.issn.1007-3418.2017.10.001..
    [25]
    DENG Y, KANG HY, XIANG HL, et al. Durability and on-treatment predictors of recompensation in entecavir-treated patients with hepatitis B and decompensated cirrhosis[J]. JHEP Rep, 2024, 6( 7): 101091. DOI: 10.1016/j.jhepr.2024.101091.
    [26]
    JI FP, LI J, LIU L, et al. High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b[J]. J Gastroenterol Hepatol, 2021, 36( 3): 767- 774. DOI: 10.1111/jgh.15192.
    [27]
    GENTILE I, SCOTTO R, COPPOLA C, et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: Results from an Italian real-life cohort(Liver Network Activity: LINA cohort)[J]. Hepatol Int, 2019, 13( 1): 66- 74. DOI: 10.1007/s12072-018-9914-6.
    [28]
    SÁNCHEZ J, GONZÁLEZ S, POYATOS P, et al. Recompensation after TIPS reduces the incidence of hepatocellular carcinoma and increases survival in patients with cirrhosis[J]. Liver Int, 2024, 44( 11): 3072- 3082. DOI: 10.1111/liv.16095.
    [29]
    XU DQ, ZHANG YY, SHANG JR, et al. Association between albumin and recompensation in patients with hepatitis B/C virus-related decompensated liver cirrhosis[J]. J Clin Hepatol, 2025, 41( 11): 2323- 2328. DOI: 10.12449/JCH251119.

    许丹青, 张映媛, 尚靖茹, 等. 乙型/丙型肝炎肝硬化失代偿期患者白蛋白水平与再代偿的关联性分析[J]. 临床肝胆病杂志, 2025, 41( 11): 2323- 2328. DOI: 10.12449/JCH251119.
    [30]
    ZHU NN, JIAO SN, ZHANG YS, et al. Analysis of influencing factors and predictive efficacy of recompensation in patients with decompensated hepatitis B cirrhosis[J]. Shandong Med J, 2025, 65( 6): 67- 72. DOI: 10.3969/j.issn.1002-266X.2025.06.014.

    朱宁宁, 焦淑宁, 张域爽, 等. 乙型肝炎肝硬化失代偿期患者再代偿的影响因素及其预测效能分析[J]. 山东医药, 2025, 65( 6): 67- 72. DOI: 10.3969/j.issn.1002-266X.2025.06.014.
    [31]
    WANG YX, WU CY, ZHOU JH, et al. Overexpression of estrogen receptor β inhibits cellular functions of human hepatic stellate cells and promotes the anti-fibrosis effect of calycosin via inhibiting STAT3 phosphorylation[J]. BMC Pharmacol Toxicol, 2022, 23( 1): 77. DOI: 10.1186/s40360-022-00617-y.
    [32]
    CHEN VL, OLIVERI A, MILLER MJ, et al. PNPLA3 genotype and diabetes identify patients with nonalcoholic fatty liver disease at high risk of incident cirrhosis[J]. Gastroenterology, 2023, 164( 6): 966- 977.e17. DOI: 10.1053/j.gastro.2023.01.040.
    [33]
    WANG Q, XIE W. Cirrhosis recompensation: Clinical complications[J]. Chin J Hepatol, 2023, 31( 7): 684- 687. DOI: 10.3760/cma.j.cn501113-20230419-00178.

    王琦, 谢雯. 肝硬化临床并发症的再代偿[J]. 中华肝脏病杂志, 2023, 31( 7): 684- 687. DOI: 10.3760/cma.j.cn501113-20230419-00178.
    [34]
    ROMANO J, SIMS OT, RICHMAN J, et al. Resolution of ascites and hepatic encephalopathy and absence of variceal bleeding in decompensated hepatitis C virus cirrhosis patients[J]. JGH Open, 2018, 2( 6): 317- 321. DOI: 10.1002/jgh3.12091.
    [35]
    XU JJ, MIAO YH, YU C, et al. The risk factors affecting the maintenance of the first re-compensatory state in patients with HBV-related decompensated cirrhosis[J]. Chin Hepatol, 2025, 30( 7): 906- 911. DOI: 10.3969/j.issn.1008-1704.2025.07.006.

    许佳珺, 缪幼菡, 俞冲, 等. 乙型肝炎相关失代偿期肝硬化首次再代偿后发生再次失代偿的风险因素分析[J]. 肝脏, 2025, 30( 7): 906- 911. DOI: 10.3969/j.issn.1008-1704.2025.07.006.
    [36]
    HE ZY, ZHOU JL, TIAN Y, et al. Two-year free of complications during antiviral therapy predicts stable re-compensation in immediate-treatment HBV-related decompensated cirrhosis[J]. Scand J Gastroenterol, 2023, 58( 4): 403- 411. DOI: 10.1080/00365521.2022.2132532.
    [37]
    LUO CL, CAO Y, XIE W. Progress in the study of antiviral therapy promotes recompensation of decompensated hepatitis B-related liver cirrhosis[J]. Chin J Pract Intern Med, 2020, 40( 6): 457- 460, 465. DOI: 10.19538/j.nk2020060104.

    骆长玲, 曹颖, 谢雯. 抗病毒治疗促进失代偿期乙型肝炎肝硬化再代偿研究进展[J]. 中国实用内科杂志, 2020, 40( 6): 457- 460, 465. DOI: 10.19538/j.nk2020060104.
    [38]
    SÁNCHEZ-TORRIJOS Y, FERNÁNDEZ-ÁLVAREZ P, ROSALES JM, et al. Prognostic implications of recompensation of decompensated cirrhosis after SVR in patients with hepatitis C[J]. J Hepatol, 2025, 83( 3): 652- 661. DOI: 10.1016/j.jhep.2025.02.041.
    [39]
    VUTIEN P, KIM NJ, MOON AM, et al. Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication[J]. Aliment Pharmacol Ther, 2024, 59( 3): 361- 371. DOI: 10.1111/apt.17802.
    [40]
    ZHENG H, LIU QQ, WU NJ, et al. Ablation for hepatocellular carcinoma in hepatitis B-related recompensated vs. compensated cirrhosis[J]. Eur Radiol, 2026, 36( 4): 2965- 2977. DOI: 10.1007/s00330-025-12135-6.
    [41]
    ZHOU LX, HE CH, DONG H, et al. Validation of Baveno VII criteria for recompensation in patients with decompensated cirrhosis treated by laparoscopic splenectomy and azygoportal disconnection[J]. J Gastroenterol, 2026, 61( 3): 314- 324. DOI: 10.1007/s00535-025-02317-w.
    [42]
    XIA S, HE ZY, WU XN, et al. Unstable recompensation: An intermediate subtype in patients with HBV-related decompensated cirrhosis[J]. Aliment Pharmacol& Ther, 2025, 63: 715- 727. DOI: 10.1111/apt.70430.
    [43]
    WANG YP, YANG XH, CAI HY, et al. Clinical research progress in different stages of recompensated cirrhosis[J]. Chin J Hepatol, 2025, 33( 8): 715- 720. DOI: 10.3760/cma.j.cn501113-20250407-00129.

    王亚萍, 杨秀涵, 蔡海奕, 等. 肝硬化再代偿不同分期的临床研究进展[J]. 中华肝脏病杂志, 2025, 33( 8): 715- 720. DOI: 10.3760/cma.j.cn501113-20250407-00129.
    [44]
    ZHUANG GH, ZHANG M, LIU Y, et al. Significant impairment of health-related quality of life in mainland Chinese patients with chronic hepatitis B: A cross-sectional survey with pair-matched healthy controls[J]. Health Qual Life Outcomes, 2014, 12( 1): 101. DOI: 10.1186/1477-7525-12-101.
    [45]
    BRENNAN PN, MACMILLAN M, MANSHIP T, et al. Autologous macrophage therapy for liver cirrhosis: A phase 2 open-label randomized controlled trial[J]. Nat Med, 2025, 31( 3): 979- 987. DOI: 10.1038/s41591-024-03406-8.
    [46]
    OU MD, GUO XZ, LI Y, et al. Differences in anxiety among patients with liver cirrhosis with different compensation abilities[J]. Am J Transl Res, 2022, 14( 7): 5187- 5194.
    [47]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines on acute-on-chronic liver failure[J]. J Hepatol, 2023, 79( 2): 461- 491. DOI: 10.1016/j.jhep.2023.04.021.
    [48]
    SEMMLER G, YANG ZW, FRITZ L, et al. Dynamics in liver stiffness measurements predict outcomes in advanced chronic liver disease[J]. Gastroenterology, 2023, 165( 4): 1041- 1052. DOI: 10.1053/j.gastro.2023.06.030.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (87) PDF downloads(29) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return